Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 448

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 448
---
 is anticipated that we will improve our disclosure controls and procedures and internal control over financial reporting primarily
through the continued development and implementation of formal policies, improved processes and documentation procedures, as well as
the continued sourcing of additional finance resources. As a result, management’s attention may be diverted from other business
concerns, which could harm our business and results of operations. To comply with these requirements, we may need to hire more employees
in the future or engage outside consultants, which will increase costs and expenses.

In
addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for
public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations
and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application
in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty
regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to
continue to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general
and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance
activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing
bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us,
which could adversely affect our business and financial results.

As
a public company subject to these rules and regulations, we may find it more expensive for it to obtain director and officer liability
insurance, and it may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could
also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on its Audit
Committee and Compensation Committee, and qualified executive officers.

As
a result of disclosure of information in filings required of a public company, our business and financial condition will become more
visible, which may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful,
our business and results of operations could be harmed, and even if the claims do not result in litigation or are resolved in its favor,
these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm its business
and